Abstract:Introduction 11 C-labeled Pittsburgh compound B ( 11 C-PiB) PET imaging can provide information for the diagnosis of Alzheimer's disease (AD) by quantifying the binding of PiB to β-amyloid deposition in the brain. Quantification index, such as standardized uptake value ratio (SUVR) and distribution volume ratio (DVR), has been exploited to effectively distinguish between healthy and subjects with AD. However, these measures require a long wait/scan time, as well as the selection of an optimal reference region. In this study, we propose an alternate measure named amyloid quantification index (AQI), which can be obtained with the first 30-min scan without the selection of the reference region. Methods 11 C-labeled Pittsburgh compound B PET scan data were obtained from the public dataset “OASIS-3”. A total of 60 mild subjects with AD and 60 healthy controls were included, with 50 used for training and 10 used for testing in each group. The proposed measure AQI combines information of clearance rate and mid-phase PIB retention in featured brain regions from the first 30-min scan. For each subject in the training set, AQI, SUVR, and DVR were calculated and used for classification by the logistic regression classifier. The receiver operating characteristic (ROC) analysis was performed to evaluate the performance of these measures. Accuracy, sensitivity, and specificity were reported. The Kruskal–Wallis test and effect size were also performed and evaluated for all measures. Then, the performance of three measures was further validated on the testing set using the same method. The correlations between these measures and clinical MMSE and CDR-SOB scores were analyzed. Results The Kruskal–Wallis test suggested that AQI, SUVR, and DVR can all differentiate between the healthy and subjects with mild AD ( p < 0.001). For the training set, ROC analysis showed that AQI achieved the best classification performance with an accuracy rate of 0.93, higher than 0.88 for SUVR and 0.89 for DVR. The effect size of AQI, SUVR, and DVR were 2.35, 2.12, and 2.06, respectively, indicating that AQI was the most effective among these measures. For the testing set, all three measures achieved less superior performance, while AQI still performed the best with the highest accuracy of 0.85. Some false-negative cases with below-threshold SUVR and DVR values were correctly identified using AQI. All three measures showed significant and comparable correlations with clinical scores ( p < 0.01). Conclusion Amyloid quantification index combines early-phase kinetic information and a certain degree of β-amyloid deposition, and can provide a better differentiating performance using the data from the first 30-min dynamic scan. Moreover, it was shown that clinically indistinguishable AD cases regarding PiB retention potentially can be correctly identified.

AMYQ: An index to standardize quantitative amyloid load across PET tracers

Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI

Quantification supports amyloid-PET visual assessment of challenging cases: results from the AMYPAD-DPMS study

Statistical Parametric Mapping in Amyloid Positron Emission Tomography

Concordance between amyloid-PET quantification and real-world visual reads: results from IDEAS

Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads

Identifying Mild Alzheimer's Disease With First 30-Min 11C-PiB PET Scan

Quantitative Brain Amyloid PET

Evaluation of novel data-driven metrics of amyloid β deposition for longitudinal PET studies

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease

New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy

Parametric Estimation of Reference Signal Intensity in the Quantification of Amyloid-Beta Deposition: an 18F-AV-45 Study.

Spatial normalization and quantification approaches of PET imaging for neurological disorders

Comparison of two semi‐quantitative amyloid PET analysis methods with and without MRI in Alzheimer’s Disease Spectrum Disorder

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease

Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods

Voxel‐level of Abnormal Β‐amyloid Accumulation and Spatiotemporal Distribution Patterns in Alzheimer’s Disease

Improved quantification of amyloid burden and associated biomarker cut-off points: results from the first amyloid Singaporean cohort with overlapping cerebrovascular disease

Sensitivity of unconstrained quantitative magnetization transfer MRI to Amyloid burden in preclinical Alzheimer's disease

Quantification of Amyloid Accumulation and Glucose Metabolism in Chinese Alzheimer’s Disease Population

Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology